On September 7, 2018 Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal Antibody-Coupled T cell Receptor (ACTR) technology platform, reported that it will present a corporate overview in a fireside chat with Charles Wilson, Chief Executive Officer, at the Morgan Stanley 16th Annual Global Healthcare Conference on Friday, September 14, 2018 at 9:20 a.m. ET in New York City (Press release, Unum Therapeutics, SEP 7, 2018, View Source [SID1234529345]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live, and available for replay on the "Events" section of Unum’s investor relations webpage (investors.unumrx.com/events) where it will be archived for approximately 90 days.

On September 6, 2018 Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing REOLYSIN (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, reported that it has entered into a Master Clinical Supply Agreement (Agreement) with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq) for use in the company’s clinical development program (Press release, Oncolytics Biotech, SEP 6, 2018, View Source [SID1234534182]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The supply agreement enables us to further investigate pelareorep’s impact on cancer treatments in combination with atezolizumab," said Dr. Matt Coffey President and CEO of Oncolytics Biotech. "We plan on incorporating this anti-PD-L1 cancer immunotherapy into our clinical program immediately. Data from these studies will broaden our experience with this drug class as we look to demonstrate the impact of pelareorep with checkpoint inhibitors."

Under this five-year Master Clinical Supply Agreement, Roche will supply atezolizumab for the proposed clinical trial with both parties having access to the clinical data.

On September 6, 2018 Gibson Oncology, LLC ("Gibson"), a privately held clinical stage company, reported that it acquired three (3) clinical non-camptothecin Topoisomerase I drugs from Linus Oncology (Press release, Gibson Oncology, SEP 6, 2018, View Source [SID1234532070]). These novel anti-cancer drugs have been tested in over 70 patients by the National Cancer Institute (NCI) and have been shown to be both safe and effective in phase I clinical trials. There are multiple United States and international patents on these agents.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The compounds acquired are indenoisoquinolines ("indenos"), a novel class of drugs which were invented and developed by Purdue University and the NCI to minimize the diarrhea and neutropenia associated with the administration of traditional camptothecin agents such as irinotecan and topotecan. The multiple phase I trials have shown effectiveness in end-stage cancer patients with solid tumors who had failed administration of up to nine (9) drugs given previously. Simultaneously, these new drugs dramatically reduce the incidence of grade 3 and 4 neutropenia and diarrhea.

In addition, Gibson strengthened its Indeno product platform through obtaining an exclusive, worldwide development and commercialization license from Purdue University for the recently discovered pro-drugs for this novel class of compounds.

With pre-clinical studies already performed which demonstrate both the effectiveness of indenos after the development of irinotecan resistance as well as synergy between PARP inhibitors and the indenos, Gibson intends to approach the FDA about phase II studies. Several academic organizations, both in the United States and in Europe, have approached Gibson about helping conduct these studies.

"We are excited to advance these novel, potent, and well-tolerated small molecule topoisomerase I inhibitor drugs in advanced stage and/or resistant cancers as a single agent or in combination with immune-oncology and targeted therapies for improved patient outcomes," stated Randall Riggs, CEO of Gibson Oncology, LLC.

On September 6, 2018 Gibson Oncology, LLC ("Gibson"), a privately held clinical stage company, reported that it acquired three (3) clinical non-camptothecin Topoisomerase I drugs from Linus Oncology (Press release, Gibson Oncology, SEP 6, 2018, View Source [SID1234532059]). These novel anti-cancer drugs have been tested in over 70 patients by the National Cancer Institute (NCI) and have been shown to be both safe and effective in phase I clinical trials. There are multiple United States and international patents on these agents.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The compounds acquired are indenoisoquinolines ("indenos"), a novel class of drugs which were invented and developed by Purdue University and the NCI to minimize the diarrhea and neutropenia associated with the administration of traditional camptothecin agents such as irinotecan and topotecan. The multiple phase I trials have shown effectiveness in end-stage cancer patients with solid tumors who had failed administration of up to nine (9) drugs given previously. Simultaneously, these new drugs dramatically reduce the incidence of grade 3 and 4 neutropenia and diarrhea.

In addition, Gibson strengthened its Indeno product platform through obtaining an exclusive, worldwide development and commercialization license from Purdue University for the recently discovered pro-drugs for this novel class of compounds.

With pre-clinical studies already performed which demonstrate both the effectiveness of indenos after the development of irinotecan resistance as well as synergy between PARP inhibitors and the indenos, Gibson intends to approach the FDA about phase II studies. Several academic organizations, both in the United States and in Europe, have approached Gibson about helping conduct these studies.

"We are excited to advance these novel, potent, and well-tolerated small molecule topoisomerase I inhibitor drugs in advanced stage and/or resistant cancers as a single agent or in combination with immune-oncology and targeted therapies for improved patient outcomes," stated Randall Riggs, CEO of Gibson Oncology, LLC.

On September 6, 2018 Advaxis, Inc. (Nasdaq: ADXS) ("Advaxis" or the "Company") reported that it intends to offer and sell in an underwritten public offering shares of its common stock, with each share of common stock to be sold together in a fixed combination with a warrant to purchase common stock (Press release, Advaxis, SEP 6, 2018, View Source [SID1234530400]). The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. are acting as joint book-running managers for the offering.

The Company intends to use the net proceeds of the offering to fund its continued research and development initiatives in connection with expanding its product pipeline and for other general corporate purposes, including, but not limited to (i) progression of ADXS-HOT into clinical research in both monotherapy and combination therapy; (ii) investment in ongoing clinical research in ADXS-PSA and ADXS-NEO, both in monotherapy and combination therapy; and (iii) investment in ongoing clinical research with axalimogene filolisbac in head and neck cancer and other HPV associated cancers, including any wind down costs associated with ongoing trials.

The securities described above will be offered by the Company pursuant to a "shelf" registration statement (File No. 333-226988) previously filed with the Securities and Exchange Commission (the "SEC") on August 23, 2018 and declared effective by the SEC on August 30, 2018.

The offering may be made only by means of a prospectus supplement and the accompanying prospectus. Before investing in the offering, you should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Advaxis has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus, which provide more information about the Company and the offering. A preliminary prospectus supplement and the accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website at View Source, copies of which can be obtained, when available, from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by email at [email protected], or from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at 212-667-8055, or by email at [email protected].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.